Breaking Cataract Patient Education Recommendation Surgery Treatment Global Spotlight: The Most Cost-Effective Countries for Cataract Surgery Eylül 10, 2025
Breaking Cornea Innovation Patient Education Treatment Surgical innovation in dry eye disease: Salivary gland transplant Ağustos 27, 2025
Breaking Clinical Trial Myopia Treatment OCT changes with low-level red light therapy for myopia in children Ağustos 26, 2025
Breaking Cataract Cornea Hyperopia LASIK Myopia Patient Education PRK Surgery Next-generation IOLs advance complex cataract care Ağustos 26, 2025
Home Industry News RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries – PR Newswire Share your love
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries PR Newswire Source: Author: | Date: 2025-08-18 07:00:00 Source: Author: | Date: 2025-08-18 07:00:00 Share your love Previous Yazı Kiora CEO to Reveal Latest Retinal Disease Therapeutic Developments at Major Ophthalmology Conference - Stock Titan Next Yazı Boehringer Ingelheim and Palatin Technologies enter into a global research collaboration and licensing agreement Related Posts FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa | Ophthalmology TimesEkim 3, 2025 AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology TimesEkim 3, 2025 Q&A: The ARCHER trial and the importance of continued GA research | Ophthalmology TimesEkim 3, 2025 Leave a ReplyCancel ReplyE-posta adresiniz yayınlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Yorum gönder
FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa | Ophthalmology TimesEkim 3, 2025
AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology TimesEkim 3, 2025
